Sarcomatoid carcinoma of the lung epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Sarcomatoid carcinoma of the lung}}
{{Sarcomatoid carcinoma of the lung}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{Trusha}}
==Overview==
==Overview==
Sarcomatoid carcinoma of the lung is a rare [[Non small cell lung cancer|non-small cell lung cancer]] with aggressive characteristics. The [[prevalence]] of sarcomatoid carcinoma of the lung is approximately 0.4 cases per 100,000 individuals worldwide. The average age of patients being diagnosed is between 65 to 75 years, male to female ratio 4:1. The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
Sarcomatoid carcinoma of the lung is a rare type of [[Non small cell lung cancer|non-small cell lung cancer]] with aggressive characteristics. There is no sufficient information on the [[incidence]] rate of sarcomatoid carcinoma of the lung. Sarcomatoid carcinoma comprises of 0.3% to 1.3% of total [[Lung cancer epidemiology and demographics|lung malignancies]].
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.


===Prevalence===
===Prevalence===
* The prevalence of sarcomatoid carcinoma of the lung is approximately 0.4 cases per 100,000 individuals worldwide.<ref name="pmid20073605">{{cite journal |vauthors=Franks TJ, Galvin JR |title=Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=1 |pages=49–54 |year=2010 |pmid=20073605 |doi=10.1043/2008-0547-RAR.1 |url=}}</ref>
* The [[prevalence]] of sarcomatoid carcinoma of the lung is approximately 0.4 cases per 100,000 individuals worldwide.<ref name="pmid20073605">{{cite journal |vauthors=Franks TJ, Galvin JR |title=Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=1 |pages=49–54 |year=2010 |pmid=20073605 |doi=10.1043/2008-0547-RAR.1 |url=}}</ref>
*Sarcomatoid carcinoma comprises of 0.3% to 1.3% of total lung malignancies.<ref>{{cite book |last1=Travis WD |last2=Brambilla E |last3=Müller-Hermelink K |last4=Harris C |last5=Kleihues C |last6=Sobin P |title=World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart |publisher=IARC Press |orig-year=2004 |pages=53-58|chapterurl=https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |isbn=ISBN 92 832 2418 3}}</ref>
*Sarcomatoid carcinoma comprises of 0.3% to 1.3% of total [[Lung cancer|lung malignancies]].<ref>{{cite book |last1=Travis WD |last2=Brambilla E |last3=Müller-Hermelink K |last4=Harris C |last5=Kleihues C |last6=Sobin P |title=World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart |publisher=IARC Press |orig-year=2004 |pages=53-58|chapterurl=https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |isbn=ISBN 92 832 2418 3}}</ref>
*The overall prevalence of sarcomatoid carcinoma of the lung is 0.1% to 0.4% of all non-small cell lung malignancies.<ref name="BrambillaTravis2001">{{cite journal|last1=Brambilla|first1=E.|last2=Travis|first2=W.D.|last3=Colby|first3=T.V.|last4=Corrin|first4=B.|last5=Shimosato|first5=Y.|title=The new World Health Organization classification of lung tumours|journal=European Respiratory Journal|volume=18|issue=6|year=2001|pages=1059–1068|issn=0903-1936|doi=10.1183/09031936.01.00275301}}</ref>
*The overall prevalence of sarcomatoid carcinoma of the lung is 0.1% to 0.4% of all [[Non small cell lung cancer|non-small cell lung malignancies]].<ref name="BrambillaTravis2001">{{cite journal|last1=Brambilla|first1=E.|last2=Travis|first2=W.D.|last3=Colby|first3=T.V.|last4=Corrin|first4=B.|last5=Shimosato|first5=Y.|title=The new World Health Organization classification of lung tumours|journal=European Respiratory Journal|volume=18|issue=6|year=2001|pages=1059–1068|issn=0903-1936|doi=10.1183/09031936.01.00275301}}</ref>


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The 3-year and 5-year [[survival rates]] for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.<ref name="RoeselTerjung2016">{{cite journal|last1=Roesel|first1=Christian|last2=Terjung|first2=Sarah|last3=Weinreich|first3=Gerhard|last4=Hager|first4=Thomas|last5=Chalvatzoulis|first5=Eleftherios|last6=Metzenmacher|first6=Martin|last7=Welter|first7=Stefan|title=Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages|journal=Interactive CardioVascular and Thoracic Surgery|year=2016|pages=ivw392|issn=1569-9293|doi=10.1093/icvts/ivw392}}</ref>.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
* Sarcomatoid carcinoma of the lung is more commonly diagnosed among patients aged 65 to 75 years old.<ref name="OuzianeBoutayeb2014">{{cite journal|last1=Ouziane|first1=Imane|last2=Boutayeb|first2=Saber|last3=Mrabti|first3=Hind|last4=Lalya|first4=Issam|last5=Rimani|first5=Mouna|last6=Errihani|first6=Hassan|title=Sarcomatoid carcinoma of the lung: A model of resistance of chemotherapy|journal=North American Journal of Medical Sciences|volume=6|issue=7|year=2014|pages=342|issn=1947-2714|doi=10.4103/1947-2714.136920}}</ref>
* Sarcomatoid carcinoma of the lung is more commonly diagnosed among patients aged 65 to 75 years old.<ref name="OuzianeBoutayeb2014">{{cite journal|last1=Ouziane|first1=Imane|last2=Boutayeb|first2=Saber|last3=Mrabti|first3=Hind|last4=Lalya|first4=Issam|last5=Rimani|first5=Mouna|last6=Errihani|first6=Hassan|title=Sarcomatoid carcinoma of the lung: A model of resistance of chemotherapy|journal=North American Journal of Medical Sciences|volume=6|issue=7|year=2014|pages=342|issn=1947-2714|doi=10.4103/1947-2714.136920}}</ref>
* Sarcomatoid carcinoma of the lung is more commonly observed among elderly patients and adults.
* Sarcomatoid carcinoma of the lung is more commonly observed among elderly patients and adults.
* Biphasic blastoma subtype is an exception and an average age of 35 years old patients being more commonly diagnosed
* Biphasic blastoma subtype is an exception with average age of 35 years old patients being more commonly diagnosed.


===Race===
===Race===
Line 28: Line 27:


===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Males are more commonly affected with sarcomatoid carcinoma of the lung than females. The male to female ratio is 4:1.<ref name="PetrovVlassov2003">{{cite journal|last1=Petrov|first1=D.B|last2=Vlassov|first2=V.I|last3=Kalaydjiev|first3=G.T|last4=Plochev|first4=M.A|last5=Obretenov|first5=E.D|last6=Stanoev|first6=V.I|last7=Danon|first7=S.E|title=Primary pulmonary sarcomas and carcinosarcomas – postoperative results and comparative survival analysis|journal=European Journal of Cardio-Thoracic Surgery|volume=23|issue=4|year=2003|pages=461–466|issn=10107940|doi=10.1016/S1010-7940(03)00024-1}}</ref><ref name="RoeselTerjung2016">{{cite journal|last1=Roesel|first1=Christian|last2=Terjung|first2=Sarah|last3=Weinreich|first3=Gerhard|last4=Hager|first4=Thomas|last5=Chalvatzoulis|first5=Eleftherios|last6=Metzenmacher|first6=Martin|last7=Welter|first7=Stefan|title=Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages|journal=Interactive CardioVascular and Thoracic Surgery|year=2016|pages=ivw392|issn=1569-9293|doi=10.1093/icvts/ivw392}}</ref><ref name="OuzianeBoutayeb2014">{{cite journal|last1=Ouziane|first1=Imane|last2=Boutayeb|first2=Saber|last3=Mrabti|first3=Hind|last4=Lalya|first4=Issam|last5=Rimani|first5=Mouna|last6=Errihani|first6=Hassan|title=Sarcomatoid carcinoma of the lung: A model of resistance of chemotherapy|journal=North American Journal of Medical Sciences|volume=6|issue=7|year=2014|pages=342|issn=1947-2714|doi=10.4103/1947-2714.136920}}</ref>
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
*Biphasic blastoma subtype is an exception, that affects men and women equally.


===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*Geographical location has no effect on the [[epidemiology]] of sarcomatoid carcinoma of the lung.
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==
Line 45: Line 38:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]
{{Tumors}}
 
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Pulmonology]]
[[Category:Lung cancer]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Surgery]]

Latest revision as of 03:49, 8 January 2019

Sarcomatoid Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcomatoid Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

Echocardiography and Ultrasound

CT-Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcomatoid carcinoma of the lung epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcomatoid carcinoma of the lung epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcomatoid carcinoma of the lung epidemiology and demographics

CDC on Sarcomatoid carcinoma of the lung epidemiology and demographics

Sarcomatoid carcinoma of the lung epidemiology and demographics in the news

Blogs on Sarcomatoid carcinoma of the lung epidemiology and demographics

Directions to Hospitals Treating Sarcomatoid carcinoma of the lung

Risk calculators and risk factors for Sarcomatoid carcinoma of the lung epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2]

Overview

Sarcomatoid carcinoma of the lung is a rare non-small cell lung cancer with aggressive characteristics. The prevalence of sarcomatoid carcinoma of the lung is approximately 0.4 cases per 100,000 individuals worldwide. The average age of patients being diagnosed is between 65 to 75 years, male to female ratio 4:1. The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.

Epidemiology and Demographics

Incidence

Sarcomatoid carcinoma of the lung is a rare type of non-small cell lung cancer with aggressive characteristics. There is no sufficient information on the incidence rate of sarcomatoid carcinoma of the lung. Sarcomatoid carcinoma comprises of 0.3% to 1.3% of total lung malignancies.

Prevalence

Case-fatality rate/Mortality rate

  • The 3-year and 5-year survival rates for patients with sarcomatoid cancer of lung are 35.8 and 28.7%.[4].

Age

  • Sarcomatoid carcinoma of the lung is more commonly diagnosed among patients aged 65 to 75 years old.[5]
  • Sarcomatoid carcinoma of the lung is more commonly observed among elderly patients and adults.
  • Biphasic blastoma subtype is an exception with average age of 35 years old patients being more commonly diagnosed.

Race

  • There is no racial predilection to sarcomatoid carcinoma of the lung.

Gender

  • Males are more commonly affected with sarcomatoid carcinoma of the lung than females. The male to female ratio is 4:1.[6][4][5]
  • Biphasic blastoma subtype is an exception, that affects men and women equally.

Region

  • Geographical location has no effect on the epidemiology of sarcomatoid carcinoma of the lung.

References

  1. Franks TJ, Galvin JR (2010). "Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis". Arch. Pathol. Lab. Med. 134 (1): 49–54. doi:10.1043/2008-0547-RAR.1. PMID 20073605.
  2. Travis WD; Brambilla E; Müller-Hermelink K; Harris C; Kleihues C; Sobin P. https://www.iarc.fr/wp-content/uploads/2018/07/BB10.pdf |chapterurl= missing title (help) (PDF). World Health Organization Classification of Tumours; Pathology and genetics of tumors of the lung, pleura, thymus, and heart. IARC Press. pp. 53–58. ISBN ISBN 92 832 2418 3 Check |isbn= value: invalid character (help).
  3. Brambilla, E.; Travis, W.D.; Colby, T.V.; Corrin, B.; Shimosato, Y. (2001). "The new World Health Organization classification of lung tumours". European Respiratory Journal. 18 (6): 1059–1068. doi:10.1183/09031936.01.00275301. ISSN 0903-1936.
  4. 4.0 4.1 Roesel, Christian; Terjung, Sarah; Weinreich, Gerhard; Hager, Thomas; Chalvatzoulis, Eleftherios; Metzenmacher, Martin; Welter, Stefan (2016). "Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages". Interactive CardioVascular and Thoracic Surgery: ivw392. doi:10.1093/icvts/ivw392. ISSN 1569-9293.
  5. 5.0 5.1 Ouziane, Imane; Boutayeb, Saber; Mrabti, Hind; Lalya, Issam; Rimani, Mouna; Errihani, Hassan (2014). "Sarcomatoid carcinoma of the lung: A model of resistance of chemotherapy". North American Journal of Medical Sciences. 6 (7): 342. doi:10.4103/1947-2714.136920. ISSN 1947-2714.
  6. Petrov, D.B; Vlassov, V.I; Kalaydjiev, G.T; Plochev, M.A; Obretenov, E.D; Stanoev, V.I; Danon, S.E (2003). "Primary pulmonary sarcomas and carcinosarcomas – postoperative results and comparative survival analysis". European Journal of Cardio-Thoracic Surgery. 23 (4): 461–466. doi:10.1016/S1010-7940(03)00024-1. ISSN 1010-7940.

Template:WH Template:WS Template:Tumors